Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data

[1] Mathers CD(2006)Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 e442-2753

[2] Loncar D(2001)Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization Circulation 104 2746-3

[3] Yusuf S(2002)Two decades of progress in preventing vascular disease Lancet 360 2-829

[4] Reddy S(2005)WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE) Bull World Health Organ 83 820-493

[5] Ounpuu S(1998)Changes in the costs of antihypertensive medications in a developing country: a study in Mexico comparing 1990 and 1996 Am J Hypertens 11 487-352

[6] Anand S(2004)Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana Journal of Pharmacy and Pharmaceutical Sciences 7 350-175

[7] Yusuf S(2004)Availability of essential drugs in two regions of Minas Gerais, Brazil Rev Panam Salud Publica 15 168-123

[8] Mendis S(2007)Retail prices of essential drugs in Brazil: an international comparison Rev Panam Salud Publica 22 118-288

[9] Abegunde D(2007)The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries Bull World Health Organ 85 279-249

[10] Yusuf S(2009)Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis Lancet 373 240-1082

[1] Mathers CD(2006)Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 e442-2753

[2] Loncar D(2001)Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization Circulation 104 2746-3

[3] Yusuf S(2002)Two decades of progress in preventing vascular disease Lancet 360 2-829

[4] Reddy S(2005)WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE) Bull World Health Organ 83 820-493

[5] Ounpuu S(1998)Changes in the costs of antihypertensive medications in a developing country: a study in Mexico comparing 1990 and 1996 Am J Hypertens 11 487-352

[6] Anand S(2004)Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana Journal of Pharmacy and Pharmaceutical Sciences 7 350-175

[7] Yusuf S(2004)Availability of essential drugs in two regions of Minas Gerais, Brazil Rev Panam Salud Publica 15 168-123

[8] Mendis S(2007)Retail prices of essential drugs in Brazil: an international comparison Rev Panam Salud Publica 22 118-288

[9] Abegunde D(2007)The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries Bull World Health Organ 85 279-249

[10] Yusuf S(2009)Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis Lancet 373 240-1082